Finance

Lists
Why is DRUG down 4,91%?
Dive Deeper
DRUG:CNSX
Bright Minds Biosciences Inc
71,00 CA$
-4,91%
(-3,67) 1D
14 հոկ, 16:00:00 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for DRUG...
Open
72,00 CA$
High
75,77 CA$
Low
71,00 CA$
Mkt. cap
700,35 մլն
Avg. vol.
848,00
Volume
708,00
52-wk high
170,00 CA$
52-wk low
68,02 CA$
EPS
-2,90 CA$
No. of employees
26
Open
72,00 CA$
High
75,77 CA$
Low
71,00 CA$
Mkt. cap
700,35 մլն
Avg. vol.
848,00
Volume
708,00
52-wk high
170,00 CA$
52-wk low
68,02 CA$
EPS
-2,90 CA$
No. of employees
26
News stories
From web sources and news partners
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc
CEO-
Employees26
Founded2017
Headquarters-
Sector-
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4,78 մլն
5,66 մլն
13,05 մլն
9,25 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
749,11 հզր
1,08 մլն
2,23 մլն
2,15 մլն
Operating expense
5,79 մլն
6,74 մլն
15,28 մլն
11,41 մլն
Total operating expenses
5,79 մլն
6,74 մլն
15,28 մլն
11,41 մլն
Operating income
-5,79 մլն
-6,74 մլն
-15,28 մլն
-11,41 մլն
Other non operating income
-123,93 հզր
-154,22 հզր
-42,48 հզր
-27,84 հզր
EBT including unusual items
-4,09 մլն
-7,57 մլն
-10,46 մլն
-2,40 մլն
EBT excluding unusual items
-4,09 մլն
-7,57 մլն
-10,46 մլն
-2,40 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
257,87 հզր
-
-
-
Net income
-4,09 մլն
-7,57 մլն
-10,46 մլն
-2,40 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,58
-0,97
-1,09
-0,24
Interest and investment income
529,54 հզր
818,26 հզր
2,69 մլն
2,79 մլն
Interest expense
-7,30 հզր
-6,58 հզր
-
-
Net interest expenses
522,24 հզր
811,69 հզր
2,69 մլն
2,79 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps